摘要
目的:探讨MACC1表达与乳腺癌临床病理学特征的相关性。方法:检索2020年05月13日前发表于PubMed、Cochrane Library等数据库中关于MACC1表达与乳腺癌的相关性研究,依次通过浏览标题、摘要和全文进行文献筛选,由2名研究者对符合纳入标准的文献进行Meta分析。结果:经筛选后采纳8项研究,共收集乳腺癌组织911例及癌旁正常组织429例。Meta分析结果示:MACC1在乳腺癌组织中阳性表达显著高于癌旁正常组织(OR=10.14,95%CI 5.32~19.32,P<0.00001)。MACC1在乳腺癌组织中阳性表达与肿瘤大小、远处转移、HER-2表达阳性、组织学分级显著相关,与ER、PR表达水平、患者是否绝经无统计学差异。结论:MACC1在乳腺癌中阳性表达明显高于癌旁正常组织,MACC1与肿瘤大小、组织学分级、远处转移及HER-2过表达相关,提示MACC1可作为乳腺癌患者预后不良的指标,尤其在HER-2型乳腺癌中有更重要的意义。
Objective:To explore the correlation between MACC1 expression and clinicopathological characteristics of breast cancer.Methods:We searched the published in PubMed, Cochrane Library and other databases on the correlation between MACC1 expression level and breast cancer before May 13,2020,and screened by reading the title, abstract and full text in turn.Two researchers conducted a Meta-analysis of the documents that met the inclusion criteria.Results:The literature screening finally included 8 studies, collecting a total of 911 cases of breast cancer tissue and 429 cases of normal tissue adjacent to cancer.The results of Meta-analysis showed that the positive expression of MACC1 in breast cancer tissues was significantly higher than that in normal tissues adjacent to cancer(OR=10.14,95%CI 5.32~19.32,P<0.000 01).In addition, the positive expression of MACC1 in breast cancer tissues was related to the tumor size, distant metastasis, HER-2 positive expression, histological grade.However, there was no statistical difference between the expression of MACC1 and the expression level of ER and PR in breast cancer, and whether the patients were menopausal or not.Conclusion:MACC1 in breast cancer is significantly higher than that in normal tissues adjacent to the cancer.MACC1 is correlated with tumor size, histological grade, distant metastasis and HER-2 overexpression, suggesting that MACC1 can be used as an indicator of poor prognosis in breast cancer patients, especially in HER-2 breast cancer, has more important significance.
作者
张洁莉
杨华
臧爱民
贾友超
李玉苗
王晓芳
陈珊珊
王婷婷
ZHANG Jieli;YANG Hua;ZANG Aimin;JIA Youchao;LI Yumiao;WANG Xiaofang;CHEN Shanshan;WANG Tingting(Department of Oncology,Affiliated Hospital of Hebei University,Hebei Baoding 071000,China;Clinical Medical School,Hebei University,Hebei Baoding 071000,China.)
出处
《现代肿瘤医学》
CAS
北大核心
2022年第9期1590-1597,共8页
Journal of Modern Oncology
基金
2018年政府资助专科能力建设和专科带头人培养项目(编号:361007)。